Palatin Technologies (PTN) Net Cash Flow (2010 - 2026)
Palatin Technologies' (PTN) quarterly Net Cash Flow came in at -$4.3 million in Q1 2026, down 381.48% on a YoY basis from $1.5 million in Q1 2025, and down 132.66% quarter-over-quarter from $13.2 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Net Cash Flow (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Net Cash Flow for 17 consecutive years, with -$4.3 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow fell 381.48% year-over-year to -$4.3 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (up 202.11% YoY), and the FY2025 full-year result was -$7.0 million, down 552.79% from the prior year.
- Net Cash Flow eased to -$4.3 million in Q1 2026 per PTN's latest filing, from $13.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $13.2 million in Q4 2025 and bottomed at -$11.6 million in Q2 2023.
- Historically, Net Cash Flow has averaged -$2.2 million across 5 years, with a median of -$1.3 million in 2025.
- The sharpest annual moves came in 2023 and 2026: Net Cash Flow jumped 43927.79% in 2023, then tumbled 381.48% in 2026.
- Over 5 years, Net Cash Flow stood at -$9036.0 in 2022, then surged by 43927.79% to $4.0 million in 2023, then plunged by 73.93% to $1.0 million in 2024, then jumped by 1180.13% to $13.2 million in 2025, then slumped by 132.66% to -$4.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$4.3 million, $13.2 million, and -$1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | -4.32 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -4.32 Mn |
| Dec 31, 2025 | 13.22 Mn |
| Sep 30, 2025 | -1.29 Mn |
| Jun 30, 2025 | 44,203.00 |
| Mar 31, 2025 | -896,542.00 |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | -7.14 Mn |
| Jun 30, 2024 | -486,692.00 |
| Mar 31, 2024 | 528,836.00 |
| Dec 31, 2023 | 3.96 Mn |
| Sep 30, 2023 | -2.46 Mn |
| Jun 30, 2023 | -11.64 Mn |
| Mar 31, 2023 | -1.55 Mn |
| Dec 31, 2022 | -9,036.00 |
| Sep 30, 2022 | -8.75 Mn |
| Jun 30, 2022 | -7.78 Mn |
| Mar 31, 2022 | -9.61 Mn |
| Dec 31, 2021 | -6.10 Mn |
| Sep 30, 2021 | -6.68 Mn |
| Jun 30, 2021 | -8.54 Mn |